Ardelyx Inc logo

ARDX

Ardelyx Inc

$1.07

Earnings Summary

Revenue
$2.53Mn
Net Profits
$-26.94Mn
Net Profit Margins
-1066.43%

Highlights

Revenue:

Ardelyx Inc’s revenue jumped 92.38% since last year same period to $2.53Mn in the Q2 2022. On a quarterly growth basis, Ardelyx Inc has generated 439.74% jump in its revenue since last 3-months.

Net Profits:

Ardelyx Inc’s net profit jumped 40.39% since last year same period to $-26.94Mn in the Q2 2022. On a quarterly growth basis, Ardelyx Inc has generated 4.04% jump in its net profits since last 3-months.

Net Profit Margins:

Ardelyx Inc’s net profit margin jumped 69.01% since last year same period to -1066.43% in the Q2 2022. On a quarterly growth basis, Ardelyx Inc has generated 82.22% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ardelyx Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.19
EPS Estimate Current Year
-0.19

Highlights

EPS Estimate Current Quarter:

Ardelyx Inc’s earning per share (EPS) estimates for the current quarter stand at -0.19 - a 13.64% jump from last quarter’s estimates.

EPS Estimate Current Year:

Ardelyx Inc’s earning per share (EPS) estimates for the current year stand at -0.19.

Key Ratios

Key ratios of the Ardelyx Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.49
Return on Equity (ROE)
-1.58
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ardelyx Inc’s return on assets (ROA) stands at -0.49.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ardelyx Inc’s return on equity (ROE) stands at -1.58.

Dividend Per Share (DPS):

Ardelyx Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.22
-0.21
4.55%

Company Information

Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

Organisation
Ardelyx Inc
Headquarters
Fremont, California, US
Employees
129
Industry
Health Technology
CEO
Michael Raab